l-670596

L-670596 is a potent, selective, orally active antagonist of the thromboxane A2/prostaglandin endoperoxide (TP) receptor. It blocks the action of thromboxane A2 on its receptor, thereby inhibiting platelet aggregation and contraction of smooth muscle cells. L-670596 has demonstrated efficacy in inhibiting arachidonic acid-induced responses in human platelets and contraction in guinea pig tracheal rings. The compound is classified as a "neutral antagonist," meaning it blocks receptor activity without exhibiting inverse agonist properties in systems with constitutively active TP receptor mutants[1][3][7]. Reported IC50 value for TP receptor inhibition is 5.5 nM[1]. Primary indications studied have revolved around cardiovascular and platelet disorders as well as asthma[3]. The developer of L-670596 is Merck[1].

Other names

L670596L-670596L 670596L-670,596PD021853PD-021853PD 021853